The effects of acute and repeated intraparaventricular (iPVN) administration of human relaxin-3 (H3) were examined on food intake, energy expenditure, and the hypothalamic-pituitary thyroid axis in male Wistar rats. An acute high dose iPVN injection of H3 significantly increased food intake 1 hour post-administration [0.4 ± 0.1g (vehicle) vs 1.6 ± 0.5g (180pmol H3), 2.4 ± 0.5g (540pmol H3) and 2.2 ± 0.5g (1620pmol H3), p< 0.05 for all doses vs vehicle]. Repeated iPVN H3 injection (180pmol/twice a day for 7 days) significantly increased cumulative food intake in ad libitum fed animals compared with vehicle [211.8 ± 7.1g (vehicle) vs 261.6 ± 6.7g (ad libitum fed H3), p< 0.05]. Plasma leptin was increased in the H3 ad libitum fed group. Plasma thyroid stimulating hormone was significantly decreased after acute and repeated administration of H3. These data suggest H3 may play a role in longterm control of food intake.
Introduction
Relaxin-3 (INSL 7) is a recently identified peptide member of the insulin superfamily, typified by the presence of an A and B chain linked by inter-and intrachain disulphide bonds [1] . Like insulin, the intervening C peptide chain of relaxin-3 is removed by proteolytic processing. The relaxin-3 gene has been identified in humans (H3) [2] , mice (M3) [2] and rats (R3) [3] , and the gene products are highly homologous. R3 and M3 mRNA expression is localized to the nucleus incertus (NI) of the brainstem [3] , a small nucleus in the central gray of the median dorsal pons near the fourth ventricle with projections to many hypothalamic nuclei. immunoreactive fibers project extensively to hypothalamic areas, including the lateral hypothalamic area, the arcuate (ARC) and paraventricular nuclei (PVN) [4; 5] .
Relaxin-3 is the cognate ligand for two previously orphan G-protein-coupled receptors, GPCR135 and GPCR142 [6; 7] . GPCR142 is a pseudogene in the rat and thus not expressed, but GPCR135 mRNA is highly expressed in the rat brain, particularly the PVN and the supraoptic nucleus (SON) [6; 8] . In addition, relaxin-3 binds to the LGR7 receptor, which also binds relaxin-1 peptide with high affinity and, although it is primarily distributed in reproductive tissues, it is also present in the CNS [9] [10] [11] .
We have recently shown for the first time, that acute intracerebroventricular and iPVN administration of low dose H3 stimulates feeding in satiated male Wistar rats in the early light phase [12] . The lowest dose of H3 to elicit a significant orexigenic response when administered iPVN was seen in the picomolar range at 18 pmol, similar to other orexigenic peptides such as ghrelin and NPY.
The aim of this study was to investigate the maximum acute orexigenic effect of iPVN H3 by using higher doses compared to earlier studies, and to establish whether acute iPVN administration of H3 may play a role in the regulation of energy expenditure and the hypothalamo-pituitary thyroid (HPT) axis. We also wished to examine the effects of chronic (7 days), repeated iPVN administration of H3 on food intake, body weight, energy expenditure and the hypothalamo-pituitary axes.
Research design and Methods

Materials
Human relaxin-3 (H3) was purchased from Phoenix Pharmaceuticals (Belmont, CA) and synthesized by the company using solid phase synthesis. Reagents for hypothalamic explant studies were supplied by BDH (Poole, Dorset, UK).
Animal studies
Male Wistar rats (Specific pathogen free, Charles River, UK) weighing 250-300g 
Intra-paraventricular cannulation and injection
Male Wistar rats underwent unilateral intra-paraventricular nuclear (iPVN) cannulation 7-10 days before feeding studies and were habituated to regular handling and injection, as previously described [13] . A 1μl iPVN injection was administered over 1 minute via a stainless steel 31-gauge injector, placed in and projecting 1mm below the end of the cannula. Spread of a 1µl injection into the PVN is reported to be limited to 1 mm 3 [14] . All compounds were dissolved in vehicle (10% acetonitrile in 0.9% saline) and studies were performed in satiated rats in the early light phase (0900 -1000h) unless otherwise stated. Cannula position was verified histologically at the end of the study [13] . Only those animals with correct cannula placement were included in the data analysis. days with ad libitum access to food and water, 2) H3 ad libitum fed group -rats received twice daily injections of H3 (180pmol) for 7 days with ad libitum access to food and water, 3) H3 pair-fed group -rats received twice daily injections of H3 (180pmol) for 7 days and were pair-fed to the median food intake of the vehicle group in the equivalent period 24 hours previously.
Body weight was measured daily at 0900h. Food was weighed immediately before and 1 hour after each injection to allow calculation of cumulative food intake and food intake in the first hour in response to each injection. A final food and body weight measurement was taken at 0900h on day 8.
Study 5: Effects of 7 day repeated iPVN administration of relaxin-3 on fat mass, plasma hormones and UCP-1 expression
Rats from study 4 were killed by decapitation on day 8 at 0900-1000h, and plasma was collected as for study 2. Plasma was assayed for pituitary hormones including TSH, prolactin, luteinizing hormone (LH) and growth hormone (GH), as well as corticosterone and leptin. Weights of epidydimal fat pads (white adipose tissue or WAT), interscapular brown adipose tissue (BAT), adrenals and testes were measured.
Expression of UCP-1 mRNA in interscapular brown adipose tissue was assessed by northern blot. RNA was extracted from BAT using Tri-reagent (Helena Biosciences, Sunderland, UK) according to the manufacturer's protocol. Northern Blot analysis was performed as previously described [15] . The filter was exposed to phosphoscreen overnight prior to quantification of UCP-1 mRNA expression using ImageQuant software (GE Healthcare, Chalfont St Giles, UK). Blots were reprobed with oligo(dT) [12] [13] [14] [15] [16] [17] [18] to enable differences in RNA loading to be corrected.
Study 6: Effect of relaxin-3 on in vitro release of hypothalamic neuropeptides
The static incubation system was used as previously described [16] . After an initial 2h equilibration period, the hypothalami were incubated for 45 min in 600 μl aCSF (basal period) before being challenged with H3 (10 nM) for 45 minutes. Finally, the viability of the tissue was verified by a 45 min exposure to 56mM KCl. At the end of each period, the aCSF was removed and frozen at -20ºC until measurement of hypothalamic hormones [Thyrotropin releasing hormone (TRH), Somatotropin release inhibitory factor (SRIF)] by RIA.
Radioimmunoassays
Plasma pituitary hormone concentrations were assayed using reagents and methods provided by the National Institute of Diabetes and Digestive Diseases and the National Hormone and Peptide Program (Dr. A. Parlow, Torrance, CA), as previously described [16] [17] [18] [19] . Hypothalamic hormones (SRIF, TRH) were assayed using inhouse radioimmunoassays (RIAs) as previously described [20; 21] . Leptin (Linco Research, Inc, St. Charles, MO), corticosterone (MP Biomedicals, Irvine, CA) and free T3 (EuroDPC Ltd, Gwynedd, UK) were measured using commercially available RIA kits.
Statistical analysis
Results are shown as mean ± S.E.M. Data from acute feeding studies, plasma hormone levels and neuropeptide expression were compared by ANOVA with posthoc LSD test (Systat, Evanston, IL). Cumulative food intake and body weight data from the repeated injection study was analyzed using marginal models with exchangeable correlation matrix and robust standard errors (Stata 8, Statacorp LP, TX). Energy expenditure parameters between control and treated group were analyzed using the Mann-Whitney U test (Stata 9, Statacorp, TX, USA).
Hypothalamic explant data was compared by paired Student t-test between control
and treated groups. In all cases, p < 0.05 was considered to be statistically significant.
Results
Study 1 : Acute effects of high dose iPVN relaxin-3 administration on food intake
A 
Study 5: Effects of 7 day repeated iPVN administration of relaxin-3 on fat mass,
UCP-1 expression and plasma hormones
Following an iPVN injection of H3 (180 pmol ( Figure 5 ). There was no difference in plasma free T3 levels between the groups [1.24 ± 0.14 pg/ml (vehicle) vs 1.53 ± 0.14 pg/ml (H3 ad libitum fed) vs 1.76 ± 0.22 pg/ml (H3 pair-fed)].
There were no differences in adrenal and testicular weight between the treatment groups and no differences in plasma prolactin, corticosterone, LH and GH plasma levels amongst the three groups (data not shown).
Study 6: Effect of relaxin-3 on in vitro release of hypothalamic neuropeptides
To 
Discussion
Little is known of the biological actions of relaxin-3. We have recently demonstrated that relaxin-3 may play a role in the regulation of food intake [12] . The aim of the current study was to investigate the maximum orexigenic response elicited by H3.
Acute iPVN administration of high dose H3 significantly increased food intake in the first and second hour post-injection in satiated rats (180-1620 pmol), and cumulatively up to 8 hours following injection. The maximum orexigenic response was achieved by a dose of 540 pmol H3 with no further increase at the higher dose of 1620 pmol H3.
Several peptides, such as NPY and AgRP, which stimulate food intake also alter energy expenditure [22] [23] [24] . We therefore examined the acute effects of H3 on both plasma TSH and other parameters of energy expenditure (VO 2 , RER and ambulatory activity). Acute iPVN administration of H3 significantly suppressed plasma TSH at 15 and 30 minutes post injection, suggesting that H3 may play a role in decreasing energy expenditure by suppression of the thyroid axis. However, there were no differences in VO 2 , RER or physical activity when the effects of acute iPVN administration of H3 were examined in the CLAMS system. It is possible that small differences in energy expenditure exist which are below the detection limit of this system. Energy expenditure is comprised of several components: thyroid hormone activity, BAT activity, activation of the sympathetic nervous system and both locomotor and non-locomotor muscle activity. Thus, although TSH was suppressed, there may be compensation by other components resulting in no overall change in energy expenditure in response to H3.
Repeated iPVN administration of H3 significantly increased food intake throughout the 7 day study. One hour food intake following injection was significantly increased in the first hour following administration in the early light phase on both day 1 and day 7 with no evidence of tachyphylaxis. Repeated 7-day iPVN administration of H3 significantly increased cumulative food intake in the ad libitum fed, H3 treated animals. However, although cumulative body weight change was increased in this group, this failed to reach significance by day 7 of the study. Plasma leptin was significantly elevated in ad libitum fed H3 treated animals and although epididymal fat pad weight was higher in the ad libitum fed H3 treated animals this did not achieve statistical significance. This elevation in plasma leptin suggests that whole body adipose tissue may be increased and it would be interesting to examine the body composition of chronic H3-treated animals in more detail. However, it is also possible that central H3 administration results in a stimulation of leptin secretion.
Since the efficacy of H3 to increase food intake did not diminish over the course of the study, it is possible a significant change in body weight may be achieved by administration of higher or more frequent doses of H3, by bilateral injection or with a longer study period.
There was no difference in cumulative body weight change between the vehicle treated and the H3-treated animals pair-fed to the food intake of the vehicle. This would suggest that there was no significant effect of H3 on energy expenditure and is in keeping with the results of acute H3 administration on metabolic parameters. In keeping with this, there was no difference in BAT UCP-1 mRNA expression between the treatment groups. There was however, a significant difference in cumulative body weight change between ad libitum fed H3 treated and H3 pair-fed animals by the end of day 7. Again, plasma TSH was significantly suppressed by repeated iPVN injection of H3. In keeping with this, a suppression of TRH release and an increase in SRIF release was seen from hypothalamic slices following administration of 10nM
H3. The sympathetic nervous system (SNS) interacts closely with the HPT axis to regulate both energy expenditure and thyroid gland responsiveness to TSH. It is possible that suppression of TSH might be accompanied by modulation of the SNS both to normalize energy expenditure and normalize plasma T3 [25] . The effects of repeated H3 administration differ from those of other orexigenic peptides such as NPY, AgRP and ghrelin. NPY, AgRP and ghrelin significantly increase food intake with repeated administration however, they also decrease energy expenditure thereby contributing to body weight gain.
In conclusion, we have demonstrated that acute iPVN administration of high dose H3 increases food intake, suppresses plasma levels of TSH but does not alter energy expenditure. We have shown for the first time that repeated iPVN administration of H3 is effective for 7 days and increases cumulative food intake and plasma leptin, but does not significantly increase body weight. Repeated iPVN H3 treatment results in a suppression of plasma TSH without alteration in plasma T3. This effect is independent of food intake, since it also occurs in pair-fed animals. The longer term effects of H3, either by virally-mediated over-expression or in transgenic animals, on body weight, energy expenditure and the HPT axis would be of great interest.
Legends Figure 1:
Effect of acute iPVN administration of H3 (180-1620 pmol) on 1 hour food intake in satiated male Wistar rats in the early light phase. * = p < 0.05 vs vehicle, n=10-12. The effect of 7-day repeated iPVN administration of vehicle or H3 (180pmol) on epididymal fat pad weight (WAT), BAT weight, UCP-1 mRNA expression, plasma leptin, plasma TSH and free T3, n=8-11.
. Vehicle -vehicle-treated, ad libitum fed; H3 -H3-treated, ad libitum fed; H3 PF -H3-treated, pair-fed to median food intake of vehicle-treated animals. Data shown as mean ± SEM. * = p < 0.05 vs vehicle
